Cleerly ISCHEMIA vs AI-CVD
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Cleerly ISCHEMIA is an AI tool focused on detailed, non-invasive assessment of coronary artery ischemia and plaque characteristics using dedicated CCTA scans for diagnosis and treatment planning. In contrast, AI-CVD specializes in opportunistic screening for a broader range of cardiovascular and multisystem disease risks by analyzing existing chest and abdominal CT scans. While both operate in cardiology AI, Cleerly targets specific ischemia diagnosis from dedicated scans, whereas AI-CVD provides broad risk factor quantification from incidental imaging.
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you need a detailed, non-invasive assessment of coronary artery disease, particularly to determine the likelihood of vessel-level ischemia and characterize coronary plaque. This tool is ideal for patients undergoing CCTA scans who require precise insights into stenosis severity and the functional significance of blockages for personalized treatment planning.
View Cleerly ISCHEMIA →Choose AI-CVD if…
Choose AI-CVD if you aim to opportunistically screen for a broad range of cardiovascular and multisystem disease risks using existing chest or abdominal CT scans. This platform is best suited for identifying hidden health risks like coronary artery calcium, aortic calcification, or abnormal cardiac chamber volumes without requiring additional imaging or disrupting existing workflows.
View AI-CVD →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | AI-CVD |
|---|---|---|
| Pricing | Contact for details | Unknown |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | AI-CVD |
|---|---|---|
| Name | Cleerly ISCHEMIA | AI-CVD |
| Company | Cleerly | HeartLung Corporation |
| Tagline | AI-Powered Precision for Non-Invasive Ischemia Detection | Advancing AI-enabled, CT-based opportunistic screening and early disease detection. |
| Description | Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | AI-CVDu00ae is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. |
| Key Features | AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization (volume, type, location), Stenosis severity assessment, 3D digital models of coronary arteries, Comprehensive interactive web-based reports, Integration with PowerScribe via API | Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and AI-CVD.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Cleerly ISCHEMIA analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding in personalized diagnosis and treatment planning for heart disease. AI-CVD performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.
Cleerly ISCHEMIA is designed to analyze CCTA scans. In contrast, AI-CVD performs opportunistic screening from existing chest and abdominal CT scans, requiring no additional imaging, radiation, contrast, or workflow disruption.
Cleerly ISCHEMIA provides AI-enabled CCTA analysis, non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization, and stenosis severity assessment. AI-CVD offers automated CT-derived measurements including coronary artery calcium (CAC) scoring, aortic/mitral valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta/pulmonary artery sizing.
Cleerly ISCHEMIA is a web-based platform with data transfer via Cleerly Proxy, which can be a VPN or virtual appliance, and offers integration with PowerScribe via API. AI-CVD is deployed via the cloud.
Cleerly ISCHEMIA is focused on determining the likelihood of coronary artery ischemia. AI-CVD is designed for opportunistic screening to identify risks for cardiovascular and multisystem diseases, including coronary heart disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes.
More Comparisons
More matchups featuring Cleerly ISCHEMIA or AI-CVD
Backers
Who funded each tool's parent company.